Proton Pump Inhibitors Linked to Asthma Complications

Adults with asthma using these acid-reducing medications may face a higher risk of exacerbations and hospital visits.

Updated on Oct. 20, 2026 in Asthma

Isometric editorial illustration of a glass mortar and pestle with medical powder on a stone surface, representing pharmaceutical research analysis. — New research suggests that patients with asthma taking proton pump inhibitors may experience a higher incidence of symptom exacerbations and medical complications. AI Illustration. Upload story photo >

Live Poll

Do you worry about the long-term health risks of taking daily acid-suppressing medication?

Adults with asthma who take proton pump inhibitors (PPIs) may face a higher risk of worsening symptoms and related health complications. New research indicates these patients often require more frequent rescue treatments compared to those not using acid-reducing medication.

Why it matters

Understanding this potential link is critical for asthma management, as the use of long-term acid suppression might unintentionally influence respiratory health. This study highlights the need for patients and doctors to carefully evaluate the necessity of PPIs in the context of persistent respiratory conditions.

A retrospective cohort analysis of 2,456 adults with asthma treated with biologics found that PPI users experienced higher rates of exacerbations at 31.9% compared to 22.6% for nonusers. The study, which reviewed patient data from 2014 to 2025, also noted increased rates of ICU admissions and respiratory infections.

The players

CHEST

An organization focused on clinical research and education in pulmonary, critical care, and sleep medicine.

TriNetX

A global health research network providing access to electronic health records for clinical studies.

The details

Proton pump inhibitors work by suppressing stomach acid, but researchers theorize that long-term acid suppression could alter the respiratory microbiome. This shift may make individuals more vulnerable to respiratory pathogens, which could explain the observed uptick in infections and acute asthma exacerbations. The analysis relied on the TriNetX U.S. Collaborative Network, examining patients with persistent PPI exposure defined as repeated prescriptions over 3 to 12 months.

The study analyzed patient data collected between 2014 and 2025.
Findings were presented in October 2026 at the CHEST Annual Meeting in Phoenix.

Health Landscape

This research follows a growing pattern of using large-scale database mining through the TriNetX U.S. Collaborative Network to uncover potential interactions between common medications and chronic conditions. It adds to the expanding focus on how systemic treatments, such as acid blockers, may influence the stability of complex respiratory diseases.

If you use proton pump inhibitors and have asthma, it is worth discussing the necessity of your acid-reflux treatment with your physician. Ask whether your current medications might be contributing to increased respiratory symptoms or if alternative management strategies are available for your needs.

The takeaway

While PPIs are common for managing acid reflux, this research suggests they could be associated with higher rates of asthma exacerbations and emergency care visits. Monitor your respiratory symptoms closely and ensure your physician is aware of all medications you take for both asthma and digestion.